Detailed Information on Publication Record
2023
NOVEL 1,3,5-TRIAZINYL AMINOBENZENESULFONAMIDES AS POTENT CARBONIC ANHYDRASE INHIBITORS
HAVRÁNKOVÁ, Eva, Jozef CSÖLLEI, Karolína ŠELIGOVÁ and C.T. SUPURANBasic information
Original name
NOVEL 1,3,5-TRIAZINYL AMINOBENZENESULFONAMIDES AS POTENT CARBONIC ANHYDRASE INHIBITORS
Authors
HAVRÁNKOVÁ, Eva (203 Czech Republic, guarantor, belonging to the institution), Jozef CSÖLLEI (703 Slovakia, belonging to the institution), Karolína ŠELIGOVÁ (203 Czech Republic, belonging to the institution) and C.T. SUPURAN (380 Italy)
Edition
51st Conference Synthesis and Analysis of Drugs, 2023
Other information
Language
English
Type of outcome
Prezentace na konferencích
Field of Study
30104 Pharmacology and pharmacy
Country of publisher
Czech Republic
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
RIV identification code
RIV/00216224:14160/23:00132044
Organization unit
Faculty of Pharmacy
Keywords in English
triazine; sulfonamide; carbonic anhydrase; inhibitors
Tags
International impact
Změněno: 7/2/2024 17:50, RNDr. Eva Havránková, Ph.D.
Abstract
V originále
Carbonic anhydrases (CA, EC 4.2.1.1) are metalloenzymes catalyzing the reversible hydration of CO2, thereby affecting the pH and related physiological processes in various organisms. In pathogenic bacteria, CAs play an essential role in survival and growth. Inhibition of bacterial CAs leads to growth retardation, growth defects and makes bacteria vulnerable to host defense mechanisms. Bacterial CAs are, therefore, very promising targets in the search for new antibiotics. In humans, 15 different isoforms of CAs can be found, including two tumor-associated (hCA IX, hCA XII). Given the above, it is clear that carbonic anhydrase inhibitors can be drugs for a whole range of diseases. However, a fundamental problem is their selectivity towards a specific isoenzyme. A series of 1,3,5-triazinyl aminobenzenesulfonamides substituted by aminoalcohol, aminostilbene, and aminochalcone structural motifs were synthesized as potential CAs inhibitors. The compounds were tested against vancomycin-resistant Enterococcus faecalis (VRE) isolates. To evaluate the selectivity of the compounds against bacterial CAs towards human CAs, the inhibitory activity of compounds against tumor-associated hCA IX and hCA XII, hCA VII isoenzyme present in the brain, and physiologically important hCA I and hCA II were determined. Tested compounds had only a negligible effect on physiologically important isoenzymes. In conclusion, newly prepared compounds have great potential as antibacterial agents with high activity and, at the same time, with high selectivity for bacterial CA compared to metabolically important hCA isoenzymes (e.g., hCA I, hCA II) found in the human body.
Links
MUNI/G/1002/2021, interní kód MU |
|